These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 38061911)

  • 21. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
    Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
    Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
    Rosenberg JE; O'Donnell PH; Balar AV; McGregor BA; Heath EI; Yu EY; Galsky MD; Hahn NM; Gartner EM; Pinelli JM; Liang SY; Melhem-Bertrandt A; Petrylak DP
    J Clin Oncol; 2019 Oct; 37(29):2592-2600. PubMed ID: 31356140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Heath EI; Rosenberg JE
    Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
    Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
    Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
    Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
    Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trend in overall survival from the start of first-line chemotherapy in patients with metastatic urothelial carcinoma.
    Yamamoto S; Kato M; Matsue T; Yukimatsu N; Takeyama Y; Otoshi T; Yamasaki T; Kuratsukuri K; Uchida J
    Jpn J Clin Oncol; 2024 Feb; 54(2):221-224. PubMed ID: 37886853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
    Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Saruta M; Takahara K; Fujita K; Minami T; Adachi T; Hirasawa Y; Hashimoto T; Ohno Y; Uemura H; Shiroki R; Azuma H; Kimura T
    Int J Urol; 2024 Apr; 31(4):342-347. PubMed ID: 38113343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetic Modeling and Exposure-Response Analysis for the Antibody-Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma.
    Zuo P; Bonate P; Garg A; Matsangou M; Tang M
    Clin Pharmacol Ther; 2024 Nov; 116(5):1278-1288. PubMed ID: 39039635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Kita Y; Otsuka H; Ito K; Hara T; Shimura S; Kawahara T; Kato M; Kanamaru S; Inoue K; Ito H; Igarashi A; Sazuka T; Takamatsu D; Hashimoto K; Abe T; Naito S; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T;
    Int J Urol; 2024 May; 31(5):552-559. PubMed ID: 38303567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study.
    Morikawa T; Naiki T; Sugiyama Y; Naiki-Ito A; Nagai T; Etani T; Iida K; Isobe T; Noda Y; Shimizu N; Aoki M; Gonda M; Banno R; Kubota H; Ando R; Umemoto Y; Kawai N; Yasui T
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer.
    Brower B; McCoy A; Ahmad H; Eitman C; Bowman IA; Rembisz J; Milowsky MI
    Front Oncol; 2024; 14():1326715. PubMed ID: 38711854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer.
    Mamtani R; Tsingas K; Parikh RB; Elsouda D; Mucha L; Fuldeore R; Hubbard RA
    Urol Oncol; 2024 Jun; 42(6):177.e1-177.e4. PubMed ID: 38503592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
    Curran C; Adib E; Kazakova V; Grivas P; Diamantopoulos LN; Alva AS; Su C; Jain RK; Tandon A; Necchi A; Marandino L; Plastini TM; Merchan JR; Sonpavde G
    Clin Genitourin Cancer; 2022 Feb; 20(1):11-16. PubMed ID: 34503934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
    Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
    Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frontline immune checkpoint inhibitors in patients ≥ 90 years with advanced urothelial cancer: a single center experience.
    Vlachou E; Johnson Ⅲ BA; Guancial E; Lombardo KA; Hoffman-Censits J
    Can J Urol; 2024 Jun; 31(3):11875-11879. PubMed ID: 38912939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
    Minato A; Kimuro R; Ohno D; Tanigawa K; Kuretake K; Matsukawa T; Takaba T; Jojima K; Harada M; Higashijima K; Nagata Y; Tomisaki I; Harada K; Fujimoto N; Miyamoto H
    Anticancer Res; 2023 Sep; 43(9):4055-4060. PubMed ID: 37648337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
    Minato A; Furubayashi N; Nagata Y; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Harada K; Nakamura M; Fujimoto N
    Curr Oncol; 2024 Feb; 31(2):862-871. PubMed ID: 38392058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.